The Food and Drug Administration ("FDA") finalized its guidance on how manufacturers of certain drug products should present quantitative efficacy and risk information in promotion directed to ...
The last draft guidance on using clinical outcomes assessments (COA) as endpoints in patient-focused drug development (PFDD) should use terminology more consistently, align more closely to other PFDD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results